Delivery Order 36F79718D0355-36C26025F0093
Award Date
12/22/24
Potential Completion Date
12/21/25
Potential Value
$1.3M
Federal Agency
Veterans Integrated Service Network 20
Awardee
Alexion Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) awarded a Delivery Order to Alexion Pharmaceuticals Inc., a foreign-owned, for-profit biopharmaceutical company, to provide the pharmaceutical drug Strensiq 80mg. The contract, valued at $522,487.40, was awarded under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) and does not have a set-aside designation. Alexion will perform the contract in Boston, Massachusetts, delivering Strensiq, which is used to treat the rare genetic disorder...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $187,948 delivery order to Alexion Pharmaceuticals Inc., doing business as Alexion, under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. Alexion will provide the drug Strensiq to the VA to treat patients from November 3, 2023 through January 31, 2024. The contract has a firm fixed price and will be performed in Boston, Massachusetts. This delivery order...
This is a firm-fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Alexion Pharmaceuticals Inc. under the Pharmaceuticals and Drugs GSA Schedule. The $285,412.29 contract is for the provision of the drug Strensiq to treat perinatal/infantile- and juvenile-onset hypophosphatasia, a rare genetic disorder. Alexion holds a $4,239,517.80 Blanket Purchase Agreement (BPA) with the VA National Acquisition Center for Strensiq, established...
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to Alexion Pharmaceuticals Inc. for the drug Soliris 300 mg vial. The contract was awarded under the GSA Pharmaceutical and Drugs Federal Supply Schedule (FSS-61-IB), with a firm-fixed-price pricing type. The contract has a ceiling value of $89,993.19 and a period of performance ending on December 31, 2015. Alexion, a global biopharmaceutical company, is the prime contractor and there are no noted...
This federal contract award, valued at $93,241.75, was issued by the Veterans Integrated Service Network 6 (VISN 6), a component of the U.S. Department of Veterans Affairs (VA), to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The contract is a Blanket Purchase Agreement (BPA) call under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, which allows for the streamlined procurement of specialized pharmaceutical products. The contract is for...
This federal contract award is for the pharmaceutical product XTANDI, awarded by the Veterans Integrated Service Network 8 (VISN 8) of the U.S. Department of Veterans Affairs (VA) to Astellas Pharma US, Inc. The $243,162 firm fixed-price delivery order was placed under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The ultimate completion date is June 30, 2016. Astellas Pharma US, Inc. is a foreign-owned, for-profit pharmaceutical manufacturer that provides...
This is a federal delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to CSL Behring L.L.C., a foreign-owned, for-profit pharmaceutical company. The contract provides medications for cancer patients, with a ceiling value of $96,646.65 and an ultimate completion date of October 20, 2016. It was awarded under the VA's Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), which has a total ceiling value of $201,482,280 and is valid through September...
The U.S. Department of Veterans Affairs (VA) awarded a $27,913.44 firm-fixed price delivery order contract to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, to provide emergency pharmaceutical orders. The contract is a delivery order under Takeda's General Services Administration (GSA) Multiple Award Schedule contract for Pharmaceuticals and Drugs. The contract supports the VA's Veterans Health Administration in delivering specialty...
This contract award is for the delivery of pharmaceutical drugs to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The prime contractor is CSL Behring L.L.C., doing business as CSL Behring LLC, a global biotherapeutics company. The contract has a potential value of $920,784.38 and is a firm fixed price delivery order against CSL Behring's Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract with the General Services Administration (GSA). The...
This federal contract award, with an ID of V797P2226D|VA797P15J0051, was made by the Veterans Integrated Service Network 12 (VISN 12) of the U.S. Department of Veterans Affairs (VA) to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The $78,091.20 firm fixed-price contract is a delivery order placed under Exelan's existing Indefinite Delivery Contract (IDC) on the VA's Pharmaceutical and Drugs Federal Supply Schedule (FSS-61-IB)...